sixty eight The FDA can approve specific styles of drug available for purchase while in the U.S. based on clinical-trials success that depend upon this kind of surrogate actions as an alternative to on immediate actions of a drug’s medical reward. Such as, FDA’s steerage, explained above, on how drug companies can establish bioequivalence be